Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H25N7O4 |
Molecular Weight | 391.4249 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(N\N=C\C2CCCCC2)=NC3=C1N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O
InChI
InChIKey=XJFMHMFFBSOEPR-DNZQAUTHSA-N
InChI=1S/C17H25N7O4/c18-14-11-15(22-17(21-14)23-20-6-9-4-2-1-3-5-9)24(8-19-11)16-13(27)12(26)10(7-25)28-16/h6,8-10,12-13,16,25-27H,1-5,7H2,(H3,18,21,22,23)/b20-6+/t10-,12-,13-,16-/m1/s1
Molecular Formula | C17H25N7O4 |
Molecular Weight | 391.4249 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Binodenoson, a selective adenosine A(2A) receptor agonist, was being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging. Binodenoson for injection under the brand name CorVue was developed for use in patients with or at risk for coronary artery disease (CAD) who are unable to perform a cardiac exercise stress test. CorVue was designed to minimize side effects such as dyspnea, flushing, heart block, and chest pain. Binodenoson did not achieve FDA approval in 2009 due to concerns over equivalence of its efficacy with adenosine.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00944970
30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:55:05 GMT 2023
by
admin
on
Sat Dec 16 17:55:05 GMT 2023
|
Record UNII |
LJA4M1L5LG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C174671
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
m2499
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
144348-08-3
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
DB04853
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1950554
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
MM-53
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
8174
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
DTXSID60869938
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
9576912
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
LJA4M1L5LG
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY | |||
|
300000034078
Created by
admin on Sat Dec 16 17:55:05 GMT 2023 , Edited by admin on Sat Dec 16 17:55:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|